治疗方法是否增进了我们对轴性脊椎关节炎的了解?

IF 5.7 2区 医学 Q1 RHEUMATOLOGY
S R Harrison, H Marzo-Ortega
{"title":"治疗方法是否增进了我们对轴性脊椎关节炎的了解?","authors":"S R Harrison, H Marzo-Ortega","doi":"10.1007/s11926-023-01097-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>An overview of how the treatment landscape of axial spondyloarthritis (axSpA) has shaped our understanding of the disease.</p><p><strong>Recent findings: </strong>Prior to the millennium, non-steroidal anti-inflammatory drugs (NSAIDs) were the only treatment for axSpA, yet only 30% of patients responded and many developed side effects. In 2003, the first biological disease-modifying drug (bDMARD) was licensed for axSpA which substantially improved outcomes in comparison to NSAIDs. In 2022, there are now several bDMARDs for axSpA; however, they too are not universally efficacious in treating axial inflammation and may have deleterious effects on extramusculoskeletal manifestations. Nevertheless, successful or not, each bDMARD gives invaluable insight into axSpA immunobiology. This review discusses how much we have learned from the use of bDMARDs in axSpA, how this has redefined our understanding of the disease, and how we might use this knowledge to develop new and better treatments for axSpA in the future.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"25 3","pages":"56-67"},"PeriodicalIF":5.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958165/pdf/","citationCount":"0","resultStr":"{\"title\":\"Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?\",\"authors\":\"S R Harrison, H Marzo-Ortega\",\"doi\":\"10.1007/s11926-023-01097-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>An overview of how the treatment landscape of axial spondyloarthritis (axSpA) has shaped our understanding of the disease.</p><p><strong>Recent findings: </strong>Prior to the millennium, non-steroidal anti-inflammatory drugs (NSAIDs) were the only treatment for axSpA, yet only 30% of patients responded and many developed side effects. In 2003, the first biological disease-modifying drug (bDMARD) was licensed for axSpA which substantially improved outcomes in comparison to NSAIDs. In 2022, there are now several bDMARDs for axSpA; however, they too are not universally efficacious in treating axial inflammation and may have deleterious effects on extramusculoskeletal manifestations. Nevertheless, successful or not, each bDMARD gives invaluable insight into axSpA immunobiology. This review discusses how much we have learned from the use of bDMARDs in axSpA, how this has redefined our understanding of the disease, and how we might use this knowledge to develop new and better treatments for axSpA in the future.</p>\",\"PeriodicalId\":10761,\"journal\":{\"name\":\"Current Rheumatology Reports\",\"volume\":\"25 3\",\"pages\":\"56-67\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958165/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Rheumatology Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11926-023-01097-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-023-01097-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

综述的目的:综述轴性脊柱关节炎(axSpA)的治疗格局如何影响了我们对该疾病的认识:千禧年之前,非甾体抗炎药(NSAIDs)是治疗轴性脊柱关节炎的唯一药物,但只有30%的患者对此有反应,许多患者还出现了副作用。2003 年,第一种生物性改变病情药物(bDMARD)获准用于治疗 axSpA,与非甾体抗炎药相比,这种药物大大改善了治疗效果。2022 年,又有几种 bDMARDs 可用于治疗 axSpA;然而,这些药物在治疗轴性炎症方面也并非普遍有效,而且可能会对肢体骨骼外表现产生有害影响。尽管如此,无论成功与否,每一种 bDMARD 都为轴索硬化症免疫生物学提供了宝贵的启示。本综述将讨论我们从轴性SpA中使用bDMARDs中学到了多少知识,这些知识如何重新定义了我们对该疾病的认识,以及我们将来如何利用这些知识为轴性SpA开发出更好的新疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

Purpose of review: An overview of how the treatment landscape of axial spondyloarthritis (axSpA) has shaped our understanding of the disease.

Recent findings: Prior to the millennium, non-steroidal anti-inflammatory drugs (NSAIDs) were the only treatment for axSpA, yet only 30% of patients responded and many developed side effects. In 2003, the first biological disease-modifying drug (bDMARD) was licensed for axSpA which substantially improved outcomes in comparison to NSAIDs. In 2022, there are now several bDMARDs for axSpA; however, they too are not universally efficacious in treating axial inflammation and may have deleterious effects on extramusculoskeletal manifestations. Nevertheless, successful or not, each bDMARD gives invaluable insight into axSpA immunobiology. This review discusses how much we have learned from the use of bDMARDs in axSpA, how this has redefined our understanding of the disease, and how we might use this knowledge to develop new and better treatments for axSpA in the future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
41
期刊介绍: This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信